BOSTON --. New research led by scientists at Beth Israel Deaconess Medical Center (BIDMC) helps explain the role of an immunosuppressive pathway associated with inflammatory bowel disease (IBD), a condition that develops in genetically susceptible individuals when the body's immune system overreacts to intestinal tissue, luminal bacteria or both.
The findings, published online in the journal Nature Communications, offer novel insights into the expression of the ecto-enzyme CD39 on immune cells and further illuminate the role of purinergic signaling in IBD.